Timothée Olivier, MD @Timothee_MD Twitter profile

Pinned Tweet

Timothée Olivier, MD

22 days

Here is a series of VISUALS regarding the neo/adjuvant setting, along with a thread explaining them and how they could be used. 1 - link to VISUALS: 2 - link to thread: 3 - much better on a laptop!

Timothée Olivier, MD

@Timothee_MD

23 days

Firstly, these novel therapies (immunotherapy and targeted therapies) have been increasingly approved over the past years. Here is the table of all 17 FDA approvals since 2018 with the link to publications, and main trials' characteristics. link: 2/6

1

0

1

2

0

10

Last Seen Profiles

@theIoveittakes

@HannahTely

@vernaalisluna

@stw_pdg

@pengen_stw

@ggongggo

@HectorUroz

@lineagew2013

@_Gamecock_

@playboikid6

@Dialogue__news

@Hairychem

@justlickitjx

@scarlett_zyan

@elenabastidasb

@pengen_stw

@J_Tizzle0812

@qmK8QUFqmPwO0

@carlyraejcombr

@jimvance4

@dul_turkporno

@NgcAnh182521961

@Maister1992

@BrawlStars

@Sena4i20

@jon_barron

@Roronoa551

@adee_chile

@rayclegg1

@naaandu_

@alexgua32249455

@mickslats

@FTC10836

@TheMasterPengu

@heiseonberg

@MilliondollarKT

Timothée Olivier, MD

@Timothee_MD

2 years

So nice to see this incredibly moving piece from @VPrasadMDMPH being published in @bariweiss Common Sense ! I’m grateful I learned this fundamental part of medicine with Vinay while rounding with him in SFGH Hospital… ?

The Cancer Stories You Never Hear

I'm often asked why I would spend my career focused on the unpredictable, unrelenting misery of cancer. Here's why.

www.thefp.com

2

25

147

Timothée Olivier, MD

@Timothee_MD

9 months

Very nice coverage by @TheFP of the recent cancelation of @VPrasadMDMPH from a medical conference. "once an invitation to speak has been extended, it should not be canceled merely because a tiny online minority dislikes the speaker. It simply incentivizes online rage, and the

2

10

85

Timothée Olivier, MD

@Timothee_MD

2 years

It was our great pleasure and honor to receive @VPrasadMDMPH in Switzerland 🇨🇭 Geneva University Hospital Oncology Unit @DOncologie Great talk as usual !

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Such a pleasure to speak to the Oncology department at University of Geneva Hospitals today on the pitfalls & successes of both observational studies and randomized trials

16

8

317

1

7

80

Timothée Olivier, MD

@Timothee_MD

9 months

On popular demand (thanks 🙏) I recorded the talk I gave recently on "How I Read Clinical Papers" = the start of a new @YouTube channel: ➡️"Primum Non Nocere" where I will be posting other videos (in english and in french)👇

3

23

72

Timothée Olivier, MD

@Timothee_MD

2 years

FUNDAMENTAL… please read this 🧵… for those naive from this concept, it will change your scientific approach for the rest of your life ! (Seriously)

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Yrs ago, researchers gave the EXACT same dataset to many teams, asking if dark skinned players got more soccer penalties There was a huge range of responses from: no to 3x as much And this was THE SAME EXACT DATASET! This has a connection to masking kids wait for it... 🧵

19

135

597

0

15

69

Timothée Olivier, MD

@Timothee_MD

2 years

I usually really enjoy your "news's show" dialogue @VPrasadMDMPH and @ZDoggMD !.. ... but your guest @RFRedberg made this episode one of my favorite !! Thank you all! Overdiagnosis, overtreatment, less is more... a must listen !👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Check out the latest #vpzd @ZDoggMD and I interview @RFRedberg Overdiagnosis and over treatment

11

20

72

2

5

65

Timothée Olivier, MD

@Timothee_MD

4 months

NATALEE phase 3 trial... deserves a sensitivity analyis ! remember the monarchE trial (adjuvant abemaciclib for 2⃣ years) --> now we have NATALEE with adjuvant ribociclib for 3⃣ years ‼️ iDFS benefit ! ... but let's have a closer look ! 1/🧵

NEJM

@NEJM

4 months

Original Article: Ribociclib plus Endocrine Therapy in Early Breast Cancer (NATALEE phase 3 trial)

16

15

67

2

18

62

Timothée Olivier, MD

@Timothee_MD

2 years

Our new paper out with @VPrasadMDMPH + check his🧵👇 The rise and fall of melflufen in 2021: -Feb=accelerated approval -July=FDA alert -Oct=US withdrawal Important lessons I hope -> we don't want this story to happen again!

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Delighted to share visiting scholar's @Timothee_MD latest paper We analyze a FDA failure: The rapid approval of "totally novel" Melflufen based on surrogate 👇 Followed by withdrawal b/c of increased deaths <8 mo later! What is going on at FDA?

7

43

109

2

19

60

Timothée Olivier, MD

@Timothee_MD

2 years

Congratulation again Vinay! and very nice essay. I think one "trait" of your approach is that nothing is never granted, you are happy to question everything anytime, in the seek of a better understanding/teaching ! This award is so deserved, thank you for the great teaching!🙏

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

I was honored this week to receive the 2022 annual Excellence in Teaching Award @UCSF @UCSF_Epibiostat During the last 7 yrs, I've taught 1000 lectures, dozens of small groups & 2 courses Wanted to share some reflections on teaching👇

67

37

667

2

9

58

Timothée Olivier, MD

@Timothee_MD

4 months

Such a great episode by @bariweiss @thehonestlypod @TheFP with Pr Roland Fryer ! Wow, really a must❗️Relevant regardless your field of interest. Academic courage is rare‼️ Thanks for pointing out Vinay !🙏

Vinay Prasad MD MPH

@VPrasadMDMPH

4 months

Just listened. Spectacular episode. Everyone in oncology could learn some courage to speak out against the many ongoing unethical trials w bad control arms and poor post protocol therapy. 👇

2

26

193

1

6

58

Timothée Olivier, MD

@Timothee_MD

1 month

LAURA trial #ASCO2024 #ASCO24 main potential limitation is understaging of a significant proportion of patients who were actually metastatic, but did not have PET-CT at enrolment? Here is a visual superimposing curves with PACIFIC-EGFR subgroup👇

4

19

59

Timothée Olivier, MD

@Timothee_MD

1 year

New paper out in BMC Cancer w/Alyson Haslam and @VPrasadMDMPH ! One of my most important work so far @vkprasadlab = MAJOR issue in modern RCTs Main findings=post-protocol treatment are not reported or substandard in most cancer RCTs ➡️can severely bias survival results❗️ 🧵1/

3

15

56

Timothée Olivier, MD

@Timothee_MD

2 years

Heading to 2023 … … I want to share 5 things I learned in 2022 with @VPrasadMDMPH doing research in the @vkprasadlab for one year. 👇

3

7

56

Timothée Olivier, MD

@Timothee_MD

2 years

New paper out in EJC ! One of the most fascinating research projects (to date !) led in @vkprasadlab , with Alyson Haslam and @VPrasadMDMPH ! Dosing and G-CSF rules in head-to-head trials. Mostly FAIR or NOT ? Make a guess and follow this thread🧵 1/8

1

22

52

Timothée Olivier, MD

@Timothee_MD

3 months

NATALEE trial, adjuvant ribociclib 21 days/28 for… 3 years! Cost alert‼️💵💲financial tox⚡️ assuming the iDFS gain is reliable (which I questioned here: ).. ..the estimated cost to avert ONE iDFS event would be $11 200 000 ‼️ here is the calculation 1/

NEJM

@NEJM

3 months

In patients with stage II or III early breast cancer, the addition of ribociclib to adjuvant hormonal therapy resulted in a significant improvement in 3-year invasive disease–free survival. Read the full NATALEE trial results and Research Summary:

3

23

78

3

14

52

Timothée Olivier, MD

@Timothee_MD

2 years

Important piece by @VPrasadMDMPH I had the chance to meet @AnilMakam in UCSF. Keep the great work Anil (clinical, teaching, research ... et al. !) Ad-hominem harassment has to stop 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

ZeroCovid doctors engage in bad behavior. My latest on Substack

24

98

368

1

7

50

Timothée Olivier, MD

@Timothee_MD

1 year

New paper out JCRCO with Vinay Prasad @vkprasadlab In 2022, US FDA approvals of PARP inhibitors in ovarian cancer = 3 withdrawals, 2 restrictions All based on either detrimental OS or lack of survival improvement🛑 --> what lessons can we draw? all is in the title 👇 1/🧵

2

9

50

Timothée Olivier, MD

@Timothee_MD

2 years

Wow! Great new video series from Vinay ! I enjoyed it a lot ! Med Twitter is alive, for sure ! Well done 👏

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

A Twitter Battle on Treating HR Risk Smoldering Myeloma I break down the debate and arguments A 3 part video series just in time for #ASH22 (a clearer video uploading to Youtube, will post link at end of video) @Plenary_Session @AaronGoodman33 PART 1 - The battle starts

10

37

203

1

7

50

Timothée Olivier, MD

@Timothee_MD

2 years

Our new paper is out now in @JAMANetworkOpen ! When a randomized trial designs a « Physicians’ choice » or « Investigators’ choice » control arm, you might think : « Great, the control arm is standard of care ! » ➡️ you may be surprised 🧵👇🏻

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology RCTs

This cross-sectional study examines the prevalence of restricted choice of treatment in control groups among physicians and investigators conducting oncology randomized clinical trials (RCTs).

jamanetwork.com

4

15

49

Timothée Olivier, MD

@Timothee_MD

2 years

"Why oncology?"... Moving piece from @VPrasadMDMPH , strongly resonates with a patient I took care of... A real doctor, I'm proud to say I learnt A LOT with Vinay while rounding in San Francisco SFGH...

Sensible Medicine

@Sensible__Med

2 years

Why oncology? on Sensible Medicine

4

10

52

0

6

48

Timothée Olivier, MD

@Timothee_MD

2 years

Our new paper out with @VPrasadMDMPH @vkprasadlab ! Nivolumab = first checkpoint inhibitor approved as neoadj ttt early lung cancer However, we highlight FOUR MAJOR limitations of the CheckMate 816 trial… A short thread👇

6

10

48

Timothée Olivier, MD

@Timothee_MD

1 year

An important moment in EBM, perfecly captured by @VPrasadMDMPH "The Cochrane Fiasco on masks" or when rigorous scientific findings are distorted to satisfy non-scientific narratives ➡️we have to be aware of this growing threat on science, scientists and people!

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

ICYMI - A play by play of the recent Cochrane Fiasco on masks

2

28

94

1

6

46

Timothée Olivier, MD

@Timothee_MD

1 year

The most transformative book in my practice of medicine, by far! It led me to work with Vinay and his research team, and it deeply influenced my clinical practice and research works. Should be read very early during med education! You wonder why? Read the book!!

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

These days we talk a lot about post protocol therapy crossover good control arms adequate power PFS as a surrogate Surrogacy analysis All of these themes got started in Malignant book Still worth your time

8

19

113

1

10

45

Timothée Olivier, MD

@Timothee_MD

1 year

Finally could watch it !! Great video about nutrition science from @VPrasadMDMPH If you feel this cartoon has some truth in it? Watch it👇and you might just end following your grandma’s advices 😊

1

8

44

Timothée Olivier, MD

@Timothee_MD

11 months

LUNAR trial: OS benefit w/ Tumor Treating Fields in metastatic NSCLC after progression If we adopt this before sham-control trials, I'm really worried this could be a HUGE medical reversal in oncology... Here is why 🧵1/5👇

4

12

43

Timothée Olivier, MD

@Timothee_MD

3 years

Again, very important findings from @vkprasadlab Congrats Alyson Haslam, @mlythoe @EmmaGreenstreet @VPrasadMDMPH ! Before reading a cost-effectiveness study : first check who is the sponsor ! Here is why 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

3 years

In our new paper in @JAMANetworkOpen we take a deep look into cost-effectiveness (CEA) studies of cancer drugs Bottom line: If a CEA study is funded by pharma, it is 40x (OMG!) more likely to find the drug is cost effective A 🧵 explaining what we found

5

63

185

1

9

41

Timothée Olivier, MD

@Timothee_MD

2 years

One important part of @vkprasadlab ’ work = Screening ! Worth your time !👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Over the last 10 years, I have published 17 articles on screening (~5% of @vkprasadlab 's focus) I am going to make them all available free in a thread If you read them all, you may think differently/ more clearly about screening #1 Most don't change OS

32

294

1K

1

16

41

Timothée Olivier, MD

@Timothee_MD

2 years

Out now in EJC, our new paper w @vkprasadlab ! We walk through some unusual contradictions among recent FDA approvals of anti-PD(L)1. $$ Which contradictions? Thread 🧵👇

3

9

40

Timothée Olivier, MD

@Timothee_MD

1 year

ADAURA #ASCO2023 Key data = 43% of patients RECEIVING subsequent anticancer ttt got OSI = Very very LOW ❗️

3

8

40

Timothée Olivier, MD

@Timothee_MD

9 months

"How I Read Clinical Papers" It was nice to talk about one of my favorite topic in the "Choosing Wisely In Oncology" workshop in Lucerne🇨🇭 + great panelists, engaging talks and discussions ! Thanks for the invitation !🙏 @SamoWorkshop

3

40

Timothée Olivier, MD

@Timothee_MD

2 years

Our new paper is out @VKprasadlab 2022 ! We analysed the confirmatory trial of sotorasib (1st KRAS inhibitor) in pts w/ lung cancer. Are the data enough for REGULAR authorization? @Swissmedic_ @EMA_News @FDAOncology ? Spoiler: WORSE survival not excluded w/ sotorasib 🛑 🧵👇

2

8

39

Timothée Olivier, MD

@Timothee_MD

2 years

« Everybody should be treated like you would treat your own mother, that’s the n°1 rule in medicine. » « Would you have your own mother on that control arm ? » If the answer is no, you have your answer! Really appreciated @VPrasadMDMPH @PlenarySession !👇

The Truth About Randomized Controlled Trials in Cancer Medicine |...

Vinay Prasad, MD MPH; Physician & Associate Professor Google Scholar: https://scholar.google.com/citations?user=ym4rwk0AAAAJ&hl=enSubstack: https://vinaypras...

www.youtube.com

4

6

38

Timothée Olivier, MD

@Timothee_MD

2 months

Vinay is addressing the elephant in the room, $$$ but few do this! The amount of money flowing into those congresses is alarming and tells us a lot about our field👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 months

Starting this Wednesday, doctors will meet in Chicago to sit in ad boards and take money from Pharma. Some thoughts on this. #asco24 #asco2024

10

32

121

3

8

39

Timothée Olivier, MD

@Timothee_MD

2 years

We had the great privilege to have Pr John P.A. Ioannidis giving a talk to our research team @vkprasadlab Impressive and fascinating works !! Thank you 🙏🏻 and to the host @VPrasadMDMPH Check it out !!👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

We were delighted at @vkprasadlab to host John Ioannidis, as he discussed some of recent papers on COVID-19. Excess death. Vaccine effectiveness. Toxicity of lockdowns. Spectacular discussion and Q& A

18

109

393

0

5

38

Timothée Olivier, MD

@Timothee_MD

1 year

Major issue. The « revolving door » financial conflict of interest, described by @jungleland an @VPrasadMDMPH in 2016… What happened since then? Not much apparently.

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

This is actually a huge problem

146

788

3K

0

5

35

Timothée Olivier, MD

@Timothee_MD

3 months

Out in @TheLancetOncol ❗️ Led by Sruthi Ranganathan w/ @VPrasadMDMPH , we reviewed the regulatory failure of sotorasib in lung❗️ 👇 -points we made right after ESMO22 -the FDA sensitivity analyses -our additionnal concerns about OS -future measures 1/3🧵

4

6

36

Timothée Olivier, MD

@Timothee_MD

2 years

📖 "Malignant" ! 👉A must read for anyone interested in medicine, oncology, and health policy in general, and readable by a very large audience ‼️ ⚠️be prepared for very concerning findings ! but @VPrasadMDMPH proposes solutions! check it out 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

The failures are so bad, I wrote a book on the topic.

2

10

56

2

6

36

Timothée Olivier, MD

@Timothee_MD

9 months

2 years ago, exactly, I joined @VPrasadMDMPH and his team for a 1-year research in @UCSF_Epibiostat This was transformative, I learned a lot, I met great researchers, which are now colleagues and friends! 🙏Vinay et al❗️ + stay tuned ! we have other projects @vkprasadlab

1

3

37

Timothée Olivier, MD

@Timothee_MD

6 months

Out today in EJC ! With @Alfdoc2 , we discuss reasons and implications of lowering the sample size in trials, based on 3 recent examples in patients with adv/metastatic lung cancer: - CodeBreaK 200 (sotorasib) - LUNAR (TTFs) - ATALANTE-1 (cancer vaccine)

3

6

37

Timothée Olivier, MD

@Timothee_MD

1 year

Some toughts about the INDIGO phase 3 trial, vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ASCO2023 - setting = residual or recurrent disease - primary EP = PFS = improved from 11.1 to 27.7 Mo (16.6) Here are some toughts 🧵 1/6

1

10

37

Timothée Olivier, MD

@Timothee_MD

1 year

Our new paper is out in @jcan_policy ! w/Claire Smith, Alyson Haslam, @Alfdoc2 , @VPrasadMDMPH We explored quality of life data in the ADJUVANT settings for recent approvals. 👉approach QoL results of ADJUVANT trials with great caution❗️ #ASCO2023 Here is why, short 🧵👇 1/5

1

14

35

Timothée Olivier, MD

@Timothee_MD

2 years

5/ A mentor can be a friend - Vinay helped me to shape my views on science. He put words on many things I had an intuitive feeling about. I’m learning continuously with him, in meetings, but also in friendly conversations! I’m grateful to have such a unique friend and mentor 🙏

2

1

36

Timothée Olivier, MD

@Timothee_MD

1 year

Looks like a great study and findings. Why are the SONIA trial results not published in the NEJM today ? I wonder...

Enrique Soto

@EnriqueSoto8

1 year

FANTASTIC and practice changing trial from the Netherlands, SONIA shows that CDK4/6i in 2nd line are as effective as in 1st line with less Toxicity and cost. This is what happens when you ask right questions and design studies to benefit patients instead of companies. #ASCO23

5

59

167

2

8

36

Timothée Olivier, MD

@Timothee_MD

1 year

New paper out @JAMAOnc ! w/ Alyson Haslam & @VPrasadMDMPH When key 🔑data lacking in trials' report.. ➡️we have uninterpretable results❗️ @vkprasadlab we give 3 examples! pembro - endometrial KN775 TDx in DESTINY-Breast04 Brentux - ECHELON1 Short 🧵👇

3

5

35

Timothée Olivier, MD

@Timothee_MD

2 years

I enjoyed my first reads of new "Sensible Medicine" substack! Pieces from @drjohnm , @adamcifu , @VPrasadMDMPH What a great idea to share ideas from diverse points of views, diverse topics ! Well done, a "must subscribe" !!👇 + BTW, very nice logo !!

About - Sensible Medicine

Common sense and original thinking in bio-medicine. Click to read Sensible Medicine, a Substack publication with tens of thousands of subscribers.

www.sensible-med.com

1

14

33

Timothée Olivier, MD

@Timothee_MD

8 months

Vinay is truly painting the big picture here ! ➡️A superb synthesis on how to approach medical research: - When to conduct RCTs (and when not to) - Strengths of RCTs (detailed) - Role of obs studies - Strengths and limitations of both Deserves a spot on your favorites list!👇

Vinay Prasad MD MPH

@VPrasadMDMPH

8 months

What every trainee needs to know about observational studies How researchers can do better My UCSF seminar

7

46

206

1

7

33

Timothée Olivier, MD

@Timothee_MD

2 years

3 doctors with different specialties debating about a recent important trial... so GREAT ! According to me, that's obvious, the winner is... ... .. . @Sensible__Med !! Well done @adamcifu , @drjohnm and @VPrasadMDMPH !

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

The Great Colonoscopy Debate @Plenary_Session @Sensible__Med A 1 hour no holds barred debate; It gets even more tumultuous @adamcifu and @drjohnm Here are the first 10 mins. But mins 11-60, pure fire Full video here: Worth an hour of your time

26

44

276

0

5

33

Timothée Olivier, MD

@Timothee_MD

1 year

This short tweet from Vinay is VERY important 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

@96_lumos we should also draw a distinction between the burden to show efficacy and the need to show harms

5

4

91

2

7

33

Timothée Olivier, MD

@Timothee_MD

14 days

As often, @VPrasadMDMPH is saying out loud what many people think but don't talk about... Does CT screening help homeless people ? 6:27 video worth your time!

CT screening for homeless people | When common sense in medicine...

Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 500+ Peer Reviewed papers,...

www.youtube.com

2

4

33

Timothée Olivier, MD

@Timothee_MD

2 years

A great educational thread on cancer trials... Vinay put it to light for many of us and documented it with research works. Great to begin 2023 !👇 (and my single best advice if your an hemonc fellow: read "Malignant"!)

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Want a primer on #Cancer trials? What are the most common errors? Calling all fellows, this will help for journal club. Here are the basics @Plenary_Session 🧵🧵

10

44

220

2

9

31

Timothée Olivier, MD

@Timothee_MD

1 year

I'm seeing papers published in top journals claiming some associations between many sorts of things and... overall survival in patients with cancer !! Wow !! remind me this from Vinay's last NEJM paper video: « Babies driven home from the hospital in a Mercedes Benz live longer

1

4

32

Timothée Olivier, MD

@Timothee_MD

1 year

Are you doubting of the utility of randomization❓ Check this short and powerful video from @VPrasadMDMPH : basics, statistics, and philosophy of randomized controlled trials, a major scientific advance of the 20th century 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

Randomized trial basics 2:1; blinding; concealment, K-M, & more Full video here: More to come here:

14

23

147

0

7

28

Timothée Olivier, MD

@Timothee_MD

2 years

Very nice piece on "placebo" in medicine, and on the relationship of humans caring for other humans... The more I practice medicine, the less I think any robot could replace such a true doctor like @adamcifu ! Thanks Adam !

Friday Reflection 6: Abrogating our Responsibility to Use Placebos

"We have to find a way to incorporate the power of the placebo, primarily in the form of caring, into medicine."

www.sensible-med.com

1

8

31

Timothée Olivier, MD

@Timothee_MD

1 year

Bishal, I admire your work, but I believe it's vital to acknowledge those who've pioneered and framed these concepts over the past decade. Missing from your crossover essay is @VPrasadMDMPH 's transformative 2016 piece, a pivotal work on the subject. 👇

Bishal Gyawali

@oncology_bg

1 year

Hot off the press in @NatRevClinOncol ! Using examples from trials presented at #ASCO23 , in this educational piece, I highlight how we should think about crossover in cancer clinical trials. Such education also forms a core theme of what we do @csoncol . In this piece, I argue

8

43

145

1

32

Timothée Olivier, MD

@Timothee_MD

2 years

New work out in @BloodAdvances ! With the great team @VPrasadMDMPH and @Berninini Oral azacitidine maintenance in patients with AML, as an exemple of « HARD » biases in RCTs Short thread 👇

2

4

31

Timothée Olivier, MD

@Timothee_MD

1 year

@TolmachovVasily @VPrasadMDMPH @Plenary_Session @DrToddLee @EBRheum @drjohnm Did you read the book "Malignant" by Vinay Prasad? If not, it might provide you with some insightful answers...

Malignant: How Bad Policy and Bad Evidence Harm People with Cancer

www.amazon.com

2

6

32

Timothée Olivier, MD

@Timothee_MD

2 years

Why I recommend this book over and over to anyone interested in oncology, trials, health policy: - you will read things you find nowhere else, really! - easy to read, many examples - there are facts, explanations, and solutions! - patient-centered, will help you to practice! 👇

Claire Alexandra Chew

@ClaireA_Chew

2 years

Having enjoyed @Plenary_Session tremendously, stoked that arrived just in time for some time off! Looking forward to this holiday read thank you @VPrasadMDMPH

4

10

46

0

10

30

Timothée Olivier, MD

@Timothee_MD

2 months

How applying FDA censoring rules can double the PFS benefit❓ Nice coverage by @VPrasadMDMPH in the Drug Development Letter of our paper recently published in EJC !👇

4

10

31

Timothée Olivier, MD

@Timothee_MD

3 years

Communication about risks, the importance of RCT and when they are needed is so important. Thread ! 👇 Nice work from @vkprasadlab Well done again Logan Powell and @VPrasadMDMPH

Vinay Prasad MD MPH

@VPrasadMDMPH

3 years

Our new paper in @EJCI_News argues that Randomized trials are necessary in medicine & PH for interventions w putative benefit & at best MED to LG effect size. Parachutes & smoking are not good counter examples Here is the explanation 🧵

8

48

142

0

8

31

Timothée Olivier, MD

@Timothee_MD

2 months

Honored to join Vinay Prasad @VPrasadMDMPH in the "Drug Development Letter" Subscribe and stay tuned for even more content !

1

5

30

Timothée Olivier, MD

@Timothee_MD

2 years

Are you interested in colon cancer screening ? And cancer screening in general ? This is THE VIDEO you need, by @VPrasadMDMPH ! 📺👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

NEJM paper now out FIRST EVER RCT of colonoscopy With 10 year follow up, 42% adherence, no gain in colon cancer death nor all cause death I break down the trial, history & interpretation in 30 mins youtube video worth your time Here is an excerpt

64

286

1K

1

9

30

Timothée Olivier, MD

@Timothee_MD

1 year

Just out in JCP ! @vkprasadlab We describe 3 reasons why financial toxicity $ is mostly uncaptured in RCTs: - ≥ 70% of sponsor-supplied drugs - 47% of trials: no $ QoL questions - some trials: $ compensation Here is where RWE could ask if QoL data mirror those of trials.

3

9

30

Timothée Olivier, MD

@Timothee_MD

2 years

Very interesting @VPrasadMDMPH reverse interview about Academic Medicine Broad topics, authentic answers and advices, and also funny ! Well done @kjmeetswrld ! sound: or video:

Plenary Session - Reverse Interview | Kristina Jenei Interviews me...

Vinay Prasad, MD MPH; Physician & Associate Professor Google Scholar: https://scholar.google.com/citations?user=ym4rwk0AAAAJ&hl=enSubstack: https://vinaypras...

www.youtube.com

1

5

30

Timothée Olivier, MD

@Timothee_MD

1 year

Great talk Vinay! Real world evidence (RWE) is a major topic in drug regulation. @VPrasadMDMPH : "RWE is a tool, but it can be a weapon [...]. We, physicians, have the oath. We must use it wisely, impartially, and for the good of patients" A must! ➡️ Audio + slides👇

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

The audio and slides are here

2

1

19

0

9

29

Timothée Olivier, MD

@Timothee_MD

1 year

re/ ADAURA #ASCO2023 @AstraZenecaUS 1 - Hazard ratio are NOT risk reduction 2 - Relative risk (not relevant here but...) are misleading ➡️misleading and technically incorrect to state : "cutting risk of death by 51%" in ADAURA 👉 with examples

0

7

29

Timothée Olivier, MD

@Timothee_MD

2 years

Most importantly: patients and aiming for better healthcare are the core motivations of all this research! Many more projects, I hope, in 2023 ! « On that positive note », Merry Christmas to all 🎄, and thanks for following!

2

28

Timothée Olivier, MD

@Timothee_MD

2 years

Doing this bookclub with Vinay is great! Very important is the structure of his analysis: part 1=current state part 2=social forces part 3=how to interpret trials! part 2 explains why we have part 1 and why we need to master part 3! Stay tuned for part 4 = SOLUTIONS!

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

The first 8 parts of #Malignant Book Club now available on YouTube @Timothee_MD and I break down the book

1

8

30

0

7

28

Timothée Olivier, MD

@Timothee_MD

9 months

Impressive work by @anushka_walia4 et al. ! Composite endpoints : any discussion w/ patients should be based on a very clear understanding of endpoints❗️ ➡️this is the paper that all oncologists need to read❗️ Well done @vkprasadlab 👏

Vinay Prasad MD MPH

@VPrasadMDMPH

9 months

This 8000 word paper by brilliant @UCSFMedicine M3 @anushka_walia4 is going to be the most interesting thing you read about PFS, EFS, DFS in oncology this year Even if you think you know these endpoints well, I promise you will learn something new 🧵🧵

13

158

642

0

7

28

Timothée Olivier, MD

@Timothee_MD

1 year

Very nice work @vkprasadlab !! Bottom line: we need CONSISTENCY in appraising the evidence… This is key to strong and reliable scientific approaches ! Well done 👍👇

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

We pulled the last 20 Cochrane reviews with results similar to Jefferson got for masking Universally, the conclusion is: this doesn't work The Cochrane Editor in Chief gives masks special treatment Embarrassing for @cochranecollab to lack consistency

5

26

115

2

3

27

Timothée Olivier, MD

@Timothee_MD

2 years

Very interesting and unfiltered comments about the recent NordICC trial (+ "Great Colonoscopy Debate"). ➡️ a very (VERY!) important point : relative risk reduction has always to be put in the context of ABSOLUTE risk reduction! @Sensible__Med again, well done 👏

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

"Yes, I am that cynical about academic medicine" An anonymous professor responds to our debate. Why anonymous? See what they say....

10

14

76

1

6

27

Timothée Olivier, MD

@Timothee_MD

1 year

I feel this 💎 @Plenary_Session episode was not enough publicized‼️ @DrToddLee , @EBRheum , @drjohnm and @VPrasadMDMPH getting into the weeds of real world evidence... ➡️are RCTs are on the spot ? THE 🔥topic ! Highly recommended for your week-end👇

4

16

27

Timothée Olivier, MD

@Timothee_MD

2 years

Woooow, do you want to learn about science, and at the same time laugh like if you were in a stand-up comedy show ?! This Plenary Session episode really has something special... Well done !👏

Plenary Session Podcast 🎙️

@Plenary_Session

2 years

5.26 - Lecture to Hawaii Medical Association Great audience

0

2

11

2

27

Timothée Olivier, MD

@Timothee_MD

2 years

Was a pleasure to interview @VPrasadMDMPH !! Real-life edition Book Club of a book that could change your thinking about many topics, oncology, health policy, drug regulation, science in general.👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

All new @Plenary_Session out in time for the weekend @Timothee_MD joins me for the first in our 9 part Malignant Book Club Pick up the book, and join us, as we cover 2 chapters a week Today is Intro & Chapter 1 Cost, Value, Benefit of Cancer drugs

1

4

23

0

5

27

Timothée Olivier, MD

@Timothee_MD

1 year

Superb video Vinay, important topic 👉 Mammography + a great tribute to David L. Sackett, the father of EBM, see the quote about preventive medicine 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

Mammography: A detailed analysis of the evidence Does it save lives?

55

120

575

5

4

26

Timothée Olivier, MD

@Timothee_MD

3 months

Another way to look at it👇 (KEYNOTE 564 adj pembro renal) - 5.2% 4y absolute OS benefit - 8.8% of control pts receiving systemic therapy upon recurrence did NOT receive an anti-PD(L)1 (red bar) - 21.9% with recurrence (excl. deaths) did NOT receive an anti-PD(L)1 (green bar)

Timothée Olivier, MD

@Timothee_MD

3 months

KEYNOTE-564 (adj pembro renal) show OS benefit BUT➡️Post-recurrence therapy is KEY in interpreting OS. Post-recurrence care in KEYNOTE-564 was clearly suboptimal. Would the benefit be seen with optimal post-recurrence care : that's the Q❗️ Visual here:

0

8

14

2

10

27

Timothée Olivier, MD

@Timothee_MD

11 months

"paternalism has been the norm of cancer screening programs" CANCER SCREENING so brilliantly explained ! by @VPrasadMDMPH on EconTalk @EconTalker This kind of essential medical insight is often missed by both the general public and doctors. A must👇

‎EconTalk on Apple Podcasts

‎Education · 2024

podcasts.apple.com

0

9

27

Timothée Olivier, MD

@Timothee_MD

3 months

The NATALEE trial, 3⃣rd tweetorial ! Let's have a look at the number of deaths in the trial... could ribociclib be responsible for an excess in mortality❓ Firstly, congrats to the investigators and @NEJM , as the breakdown of iDFS is available. 1/

1

6

24

Timothée Olivier, MD

@Timothee_MD

2 years

Spot on @ColeWayant , @ManniMD1 , @VPrasadMDMPH ! 17 accelerated approvals in 2021 () Is it always good? Your piece provide ways to improvements ! We don't want the Melflufen story to happen again… ()

Reporting of trials with possible detrimental overall survival: a patient advocate perspective

On Oct 22, 2021, melflufen, a novel peptide–drug conjugate intended for use in relapsed or refractory multiple myeloma, was withdrawn from the US market by the pharmaceutical company that developed...

www.thelancet.com

Cole Wayant

@ColeWayant

2 years

FDA accelerated approval has the potential to fundamentally change cancer outcomes for patients. Several limitations may prevent that. Read more here 👇🏼👇🏼👇🏼 w/ @ManniMD1 @VPrasadMDMPH

5

21

2

9

26

Timothée Olivier, MD

@Timothee_MD

2 years

Here are UNIQUE analyses by @VPrasadMDMPH of works presented #ASCO22 #ASCO2022 No matter your background, if you are interested in patient advocacy and critical appraisal: - read the paper - note your points - and watch very stimulating (and 👍 for long term memory)!

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

A thread of my #ASCO22 #ASCO2022 videos for @Plenary_Session I aim to be educational & what discussant should have said Suggestions accepted in replies #1 SHINE - I-BR vs BR, Mantle Cell PFS #2 DYNAMIC - CT DNA guided Adjuvant CRC #3 DESTINY BREAST-04

9

10

78

2

5

23

Timothée Olivier, MD

@Timothee_MD

2 years

A great episode, Vinay also asked unusual and tough questions, allowing guests to provide fantastic and original insights !! Thanks @sanamloghavi @DavidSteensma @AaronGoodman33 @VPrasadMDMPH A refreshing and spontaneous discussion about academy/industry 👇

Plenary Session Podcast 🎙️

@Plenary_Session

2 years

Just in time for the weekend @sanamloghavi @AaronGoodman33 @DavidSteensma Industry vs the Academy; Challenges; Downsides; Regrets and More

3

6

31

1

3

25

Timothée Olivier, MD

@Timothee_MD

1 year

Fantastic video, all you need to know to "enter" into the complex question of what should be the control arm ? as usual, Vinay, great !

Placebo Control Arms | Vaccines - Which one? | Active vs Passive/...

Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 450+ Peer Reviewed papers,...

www.youtube.com

3

5

25

Timothée Olivier, MD

@Timothee_MD

4 months

Out in EJC, our new work led by the great @pharmatinib a collective efforts @vkprasadlab ! "When cisplatin is in shortage the average increase in price per patient, when adhering to ASCO substitutions, was $46,943." ➡️ important findings for health policy ! 1/2

2

4

25

Timothée Olivier, MD

@Timothee_MD

2 months

One of the most important and practice-changing piece this year. Everyone treating patients with melanoma should read this‼️ Conclusions are supported by clinical trials data and real-world outcome. Great work by @DoniaMarco & @VPrasadMDMPH 👇 (+link )

JAMA Oncology

@JAMAOnc

2 months

Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint inhibition therapy.

0

6

16

3

6

23

Timothée Olivier, MD

@Timothee_MD

2 years

Our new paper is out in @JAMANetworkOpen ! Led by Idine Mousavi, with @VPrasadMDMPH 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Our new paper OUT TODAY We calculate the cost to avert a SINGLE DFS event of all the new "game-changer" Cancer drugs Median is 1.6 MILLION USD, up to 2.6 MIL!! These costs will BANKRUPT us Based on power calcs, this is the trial GOAL! No surprise Sad!

9

24

115

0

5

25

Timothée Olivier, MD

@Timothee_MD

2 years

A must-listen @Plenary_Session episode + we can feel the "in-person" ambiance ! @AaronGoodman33 is spot on... we are exposed too late during med-ed to common sense in critical appraisal ... but I feel things are changing! 👇

Aaron Goodman - “Papa Heme”

@AaronGoodman33

2 years

Solid @Plenary_Session in person chat in San Diego. 5.16 - Aaron Goodman UCSD by Plenary Session on #SoundCloud

3

7

28

1

5

24

Timothée Olivier, MD

@Timothee_MD

1 year

Evidence-based medicine = EBM @VPrasadMDMPH inverviewing @carlheneghan and Tom Jefferson Thanks 🙏for articulating so clearly some key core principles of EBM: relevant to COVID19 + oncology + every topic in medicine ! Superb episode Vinay, well done 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

This morning I interviewed Tom Jefferson and @carlheneghan A great summary of EBM Cochrane Mask Controversy | Tom Jefferson, Carl Heneghan Interview | Wil... via @YouTube

10

72

220

0

6

22

Timothée Olivier, MD

@Timothee_MD

2 years

Logan Powell is an outstanding member of our team @vkprasadlab : researcher, medical student, ironman competitor !... ...and most importantly shows human traits that make me confident for the upcoming generation of doctors ! Consider supporting him !👇

VKPrasadLab

@vkprasadlab

2 years

Medical Student and VKPrasadLab member, Logan Powell, is participating in an IRONMAN triathlon to raise money for charity – donations can be made at the link below!

1

3

19

2

23

Timothée Olivier, MD

@Timothee_MD

2 years

So many passionating works. @VPrasadMDMPH is a terrific mentor and research leader ! So happy to be part of the @vkprasadlab team !

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Really enjoyed working on these academic papers this last year with many talented people, and the welcome break away from thinking about botched COVID19 policy

9

19

208

1

4

23

Timothée Olivier, MD

@Timothee_MD

2 years

Very nice work from @anushka_walia4 ! with Alyson Haslam and @VPrasadMDMPH The surrogates are on the rise📈 but are they validated surrogates❓ Check it out 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

New analysis led by terrific @ucsf @UCSFMedicine @UCSF_Epibiostat med-student @anushka_walia4 studies FDA validation of surrogate endpoints👇 Strangely 87% FDA doesn't not do a literature review for relevant studies & only 1 finds strong correlation 🤔

2

11

45

1

4

23

Timothée Olivier, MD

@Timothee_MD

13 days

Our new work is out in EJC, led by @AlysonHaslam , with @SruthiRanganat1 and @VPrasadMDMPH ! We argue against the routine use of CDK4/6 inhibitors as adjuvant therapy in ER+ /HER2- early breast cancer See why in this thread !🧵1/7 paper here :

2

11

24

Timothée Olivier, MD

@Timothee_MD

24 days

Our new paper out in @JAMAOnc ! co-authored with @AlysonHaslam and @VPrasadMDMPH "Is it better to treat all patients early on, or to spare those who are already cured and only treat those who relapse?" Here are some clues, and my coverage of our work👇:

3

5

23

Timothée Olivier, MD

@Timothee_MD

10 months

ALL (almost) you want to know about immunotherapy in cancer ! This is ... real oncology ! Both Vinay and Alfredo talks were amazing👏👍 + special congrats to @DoniaMarco to organize such a unique event !

Vinay Prasad MD MPH

@VPrasadMDMPH

10 months

Just OUT. My lecture and @Alfdoc2 's lecture in @DoniaMarco 's course on Immunotherapy This talk is for anyone in cancer medicine. Worth your time @Timothee_MD

3

12

47

1

6

22

Timothée Olivier, MD

@Timothee_MD

2 years

Check out our new paper out !! We propose an original trial design, Led by amazing Logan Powell! I really enjoyed being part of this one… @vkprasadlab 👇

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Out now-we have an OA paper w a *NEW* trial design The "Is it a parachute trial?" design! Multi-experimental arms, which automatically trigger randomization if all arms fail to achieve near perfection Solves ethical & technical issues! Check it out!🧵

2

18

76

0

8

22

Timothée Olivier, MD

@Timothee_MD

2 years

Nice message from our research team leader @VPrasadMDMPH ! Yes, working hard, + always trying to think more about research questions, be ready to question our findings, and have others views, a great team ! + research meeting fun and entertaining !!

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

Just over halfway through the year, and we have been working hard in @vkprasadlab 👇 Here is a list of peer review academic papers we have published this year I always learn so much from doing research w smarter collaborators. Really helps me improve at reading articles.

1

6

48

0

4

22

Timothée Olivier, MD

@Timothee_MD

5 months

One of my favorite paper with Vinay ! One goal : to make informative censoring considered as important as the control arm or post-progression therapy ! Check out the paper (open access)👇 + More to come soon !

Vinay Prasad MD MPH

@VPrasadMDMPH

5 months

For a second, I thought we were scooped! Whew! In our recent paper, led by @Timothee_MD , we explore a new challenge in censoring Equal rates of censoring but for different reasons. Such censoring can still be informative, i.e. bias results Especially 4 PFS @ManniMD1

3

15

57

1

6

21

Timothée Olivier, MD

@Timothee_MD

2 years

1/ The broad view is always relevant - Context of the evidence, limits of it! history of science, history of statistics, role of social forces… This is what you get with Vinay and what I always think about in our projects…

1

22

Timothée Olivier, MD

@Timothee_MD

1 month

Health-Related QoL data in ALINA (alectinib adjuvant for 2 years) will be presented tomorrow #ASCO24 #ASCO2024 Quality-of-life in adjuvant settings! @Alfdoc2 Here is why @VPrasadMDMPH and I suspect the data will have an overall high risk of bias!👇

0

7

22

Timothée Olivier, MD

@Timothee_MD

1 year

Spot on ! A very important reminder: REAL shared-decision is too often lacking when considering cancer screening. It needs : - time - knowledge of the data - exploring patient’ values (a pilar of EBM BTW) - open mind👇

Vinay Prasad MD MPH

@VPrasadMDMPH

1 year

In my latest for @Sensible__Med , I remember a man I took care of years ago who underwent lung cancer screening. Sometimes people think that cancer screening has no downsides, but it does, particularly when the evidence is weak

16

27

127

0

6

22

Timothée Olivier, MD

@Timothee_MD

2 months

Let’s start the ➡️Friday’s Gem 💎 novel section of the Drug Development Letter with @ManniMD1 and @AaronGoodman33 recent @NatRevClinOncol great comment! “Overtreatment in multiple myeloma and its precursor states” ❗️👇

2

6

21

Timothée Olivier, MD

@Timothee_MD

2 years

Great @Plenary_Session episode! True leaders are free thinkers, open-minded, and committed to patients and education of peers. This is what is truly inspiring. Thank you @JackWestMD for doing that as a "restless soul"

Vinay Prasad MD MPH

@VPrasadMDMPH

2 years

80 minutes with @JackWestMD Lung cancer Podcasting/ TeleHealth Keynote 189 CM816 Adaura/ Pacific Driver mutations Staging/ Brain MR Adjuvant Nested and Adjacent subgroups and much more... @Plenary_Session

4

12

79

0

4

22